Burcin Cakan Demirel
Overview
Explore the profile of Burcin Cakan Demirel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kahraman S, Hizal M, Demirel B, Guven D, Gumusay O, Uluc B, et al.
BMC Cancer
. 2024 Dec;
24(1):1592.
PMID: 39736618
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2-...
2.
Karan C, Yaren A, Demirel B, Dogan T, Ozdemir M, Demiray A, et al.
Cancer Diagn Progn
. 2023 Nov;
3(6):706-715.
PMID: 37927800
Background/aim: Advanced bladder cancer (BC) is associated with an inflammatory nature and poor prognosis Inflammatory biomarkers are potential predictors in BC. We conducted a study to assess the prognostic value...
3.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel B, et al.
Future Oncol
. 2023 May;
19(10):727-736.
PMID: 37133230
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The authors report retrospective...
4.
Karacin C, Oksuzoglu B, Demirci A, Keskinkilic M, Baytemur N, Yilmaz F, et al.
BMC Cancer
. 2023 Feb;
23(1):192.
PMID: 36849943
No abstract available.
5.
Karacin C, Oksuzoglu B, Demirci A, Keskinkilic M, Baytemur N, Yilmaz F, et al.
BMC Cancer
. 2023 Feb;
23(1):136.
PMID: 36765293
Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which...
6.
Demiray A, Yaren A, Sungurtekin U, Baltalarli P, Demirkan N, Herek D, et al.
J Oncol
. 2022 Sep;
2022:4108677.
PMID: 36157223
Aim: The current standard treatment of locally advanced rectal carcinoma is total mesorectal excision and postoperative adjuvant chemotherapy after neoadjuvant concurrent chemoradiotherapy (NCRT). Many studies have shown that pathological complete...
7.
Demiray A, Demiray A, Yaren A, Taskoylu B, Dogu G, Degirmencioglu S, et al.
Turk J Gastroenterol
. 2022 Aug;
33(8):696-703.
PMID: 35943151
Background: First-line treatments for metastatic pancreatic cancer are chemotherapy regimens consisting of 5-fluorouracil or gemcitabine; however, there are no biomarkers to help determine which patients might benefit from which treatment...
8.
Goktas Aydin S, Demirel B, Bilici A, Topcu A, Aykan M, Kahraman S, et al.
Curr Med Res Opin
. 2022 Aug;
38(10):1751-1758.
PMID: 35916475
Objectives: Advanced-stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study, we aimed to...